---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000045"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:33:36.001005+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Keros Q1 net income $148.5M on Takeda license; cash $720.5M; KER-065 Phase 2 plan Q1 2026

## Summary
- Net income of $148.5M vs net loss of $43.1M YoY; revenue driven by Takeda license agreement.
- Research and development expenses $48.7M, up from $38.3M YoY, due to pipeline advancement.
- Cash and cash equivalents $720.5M expected to fund operations into 2029.
- Phase 1 KER-065 topline met objectives; plan to start Phase 2 in Q1 2026 after regulatory engagement.
- Phase 2 TROPOS trial of cibotercept (KER-012) in PAH data expected Q2 2025; Board reviewing strategic alternatives.

## SEC filing metadata
- accession: 0001664710-25-000045
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000045/0001664710-25-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000045/kros-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000045
- JSON: https://secwatch.observer/filing/0001664710-25-000045.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.